【摘要】 目的探讨血清肿瘤标志物胸苷激酶1(TK1)、β2微球蛋白(β2-MG)检测在恶性淋巴瘤诊断、治疗中的临床意义。方法采用免疫印迹增强化学发光法及放射免疫分析法检测了45例恶性淋巴瘤患者(L组)、38例健康对照者(C组)血清TK1、β2-MG的水平。结果 L组血清TK1和β2-MG水平分别为(5.46±3.39)pmol/L和(3.60±1.45)mg/L,显著高于C组的(0.83±0.31)pmol/L和(1.82±0.47)mg/L(P<0.01);血清TK1阳性率为91.1%,明显高于血清β2-MG阳性率62.2%(P<0.01)。30例恶性淋巴瘤患者化疗后血清TK1、β2-MG水平显著下降(P<0.01),并与C组相仿(P>0.05)。结论血清TK1、β2-MG检测对恶性淋巴瘤的早期诊断、治疗效果判断及预后评估有重要的临床意义。更多还原

【Abstract】 Objective To investigate the value of detecting serum thymidine kinase 1(TK1) and β2-MGicroglobulin(β2-MG) in the diagnosis of malignant lymphoma.Methods Serum levels of TK1 and β2-MG were measured with Western blot enhanced chemiluminescence assay and radioimmunoassay in 45 cases with malignant lymphoma(group L) and 38 cases of healthy volunteers(group C).ResultsSerum TK1 and β2-MG in group L were(5.46±3.39) pmol/L and(3.60±1.45) mg/L,which were significantly higher than(0.83± 0.31) pmol/L and(1.82 ± 0.47) mg/L in group C(P<0.01).The positive rate of TK1 in serum was 91.1%,which was higher than 62.2% of serum β2-MG(P<0.01).Compared to before,serum levels of TK1 and β2-MG were obviously decreased in 30 cases of malignant lymphoma after chemotherapy(P<0.01),which nearly reached to the levels in group C.ConclusionThe detection of TKl and β2-MG in serum has an important clinical value in the early diagnosis,and the evaluation of treatment and prognosis in the patients with malignant lymphoma.更多还原